DEDICATED TO RADICALLY IMPROVING HEALTH OUTCOMES FOR PATIENTS BY ADDRESSING DIRE UNMET MEDICAL NEEDS
The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for patients with unmet needs in oncology with Resistance Mechanism Inhibitors (RMIs). This new class of therapeutics simultaneously targets multiple hallmarks of cancer progression and have demonstrated dramatic preclinical efficacy as monotherapy and in strategic combinations. OS2966 is our first-in-class lead platform drug program targeted against CD29 with FDA Orphan Drug Designations in the treatment of glioblastoma and ovarian cancer. A phase I clinical trial is anticipated in 2018.